Cancer4 March 2026· 8 min read
NHS expands abiraterone access for high-risk prostate
NHS England has widened abiraterone acetate access for adults with high-risk non-metastatic prostate cancer, with treatment expected to reach eligible patients within weeks. The change matters because
By Tom Okafor, Clinical Trials Correspondent